Ascendis Pharma Gets U.S. Orphan Drug Exclusivity For YORVIPATH In Adult Hypoparathyroidism
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Ascendis Pharma A/S (ASND) said that the U.S. Food & Drug Administration has granted Orphan Drug exclusivity to YORVIPATH (palopegteriparatide, developed as TransCon PTH), providing seven years of market exclusivity for YORVIPATH in the United States for the treatment
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-769720227_2400a-31d6e8ea286f4dea9c854eaf18af463c.jpg "Planning for Retirement? Start With These 5 Steps")
:max_bytes(150000):strip_icc():format(jpeg)/Primary-Image-how-to-trade-0dte-options-7481013-c9af6887219942dc9c8c9374963b51ec.jpg "How to Trade 0DTE Options")
